ReviewCurrent gastroenterology reports2017
Quality Improvement Initiatives in Inflammatory Bowel Disease.
Review in Current gastroenterology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Models of outpatient care delivery in inflammatory bowel disease: a scoping review.Journal of the Canadian Association of Gastroenterology · 2025Article
- Prolonged time to treatment of biologics in inflammatory bowel disease: disparities from a retrospective study in a tertiary referral centre in the UK.BMC gastroenterology · 2025Article
- A randomized controlled trial of a proactive analgesic protocol demonstrates reduced opioid use among hospitalized adults with inflammatory bowel disease.Scientific reports · 2023Article
- Concordance and Discordance Between Patient-reported Remission, Patient-reported Outcomes, and Physician Global Assessment.Inflammatory bowel diseases · 2023Article
- Risks of Development of COVID-19 Among Patients With Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection.Crohn's & colitis 360 · 2022Article
- Subjective Needs and Thoughts for the Treatment of Patients with Inflammatory Bowel Disease: Applying Q Methodology.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2021Article
- Clinical applications of artificial intelligence and machine learning-based methods in inflammatory bowel disease.Journal of gastroenterology and hepatology · 2021Article
- Pain in Inflammatory Bowel Disease Is Not Improved During Hospitalization: The Impact of Opioids on Pain and Healthcare Utilization.Digestive diseases and sciences · 2020Article
- Integrated Care Models: Optimizing Adult Ambulatory Care in Inflammatory Bowel Disease.Journal of the Canadian Association of Gastroenterology · 2020Article
- Sustained Improvement in Inflammatory Bowel Disease Quality Measures Using an Electronic Health Record Intervention.Applied clinical informatics · 2019Article
- Improving treatment of patients with inflammatory bowel diseases: a controlled trial of a multifaceted intervention in two German cities.International journal of colorectal disease · 2019Article
- Improving the quality of care for inflammatory bowel disease.Intestinal research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis article serves as an overview of several quality improvement initiatives in inflammatory bowel disease (IBD). RECENT
findingsIBD is associated with significant variation in care, suggesting poor quality of care. There have been several efforts to improve the quality of care for patients with IBD. Quality improvement (QI) initiatives in IBD are intended to be patient-centric, improve outcomes for individuals and populations, and reduce costs-all consistent with "the triple aim" put forth by the Institute for Healthcare Improvement (IHI). Current QI initiatives include the development of quality measure sets to standardize processes and outcomes, learning health systems to foster collaborative improvement, and patient-centered medical homes specific to patients with IBD in shared risk models of care. Some of these programs have demonstrated early success in improving patient outcomes, reducing costs, improving patient satisfaction, and facilitating patient engagement. However, further studies are needed to evaluate and compare the effects of these programs over time on clinical outcomes in order to demonstrate long-term value and sustainability.
Indexed as
Identifiers
28730508What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.